Synthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK1 receptor quantitation: ([18F]SPA-RQ).
暂无分享,去创建一个
Tove Grönroos | Merja Haaparanta | Jarmo Hietala | Christine Ryan | Richard Hargreaves | Olli Eskola | Sarita Forsback | J. Hietala | H. Burns | T. Viljanen | R. Hargreaves | T. Grönroos | R. Gibson | M. Haaparanta | O. Solin | J. Bergman | P. Lehikoinen | S. Forsback | Pertti Lehikoinen | Tapio Viljanen | Olof Solin | O. Eskola | T. Hamill | C. Ryan | Terence G Hamill | H Donald Burns | Jörgen Bergman | Raymond Gibson | Gerard Kieczykowski | G. Kieczykowski | Gerard R. Kieczykowski
[1] P. Thadeio,et al. Discovery of a potent substance P antagonist: recognition of the key molecular determinant. , 1992, Journal of medicinal chemistry.
[2] C. Maggi,et al. Tachykinin receptors and tachykinin receptor antagonists. , 1993, Journal of autonomic pharmacology.
[3] M S Kramer,et al. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. , 1999, Trends in pharmacological sciences.
[4] F. Nantel,et al. Pharmacology of neurokinin receptors , 1991, Biopolymers.
[5] T. Visser,et al. In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] R G Hill,et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. , 1998, Science.
[7] R. Hosoki,et al. Pharmacological profiles of new orally active nonpeptide tachykinin NK1 receptor antagonists. , 1998, European journal of pharmacology.
[8] M. Kris,et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. , 1999, The New England journal of medicine.
[9] T J Mangner,et al. Synthesis of a nonpeptide carbon-11 labeled substance P antagonist for PET studies. , 1993, Nuclear medicine and biology.
[10] S. Ko,et al. 2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N - methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models. , 1998, Journal of medicinal chemistry.
[11] Anne W. Schmidt,et al. Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor. , 1996, The Journal of pharmacology and experimental therapeutics.
[12] C. Maggi,et al. The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles , 1998, Neuropeptides.
[13] S. Iyengar,et al. LY303870, a centrally active neurokinin-1 antagonist with a long duration of action. , 1997, The Journal of pharmacology and experimental therapeutics.
[14] Stephen P. Hunt,et al. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P , 1998, Nature.
[15] J. Lowe,et al. A potent nonpeptide antagonist of the substance P (NK1) receptor. , 1991, Science.
[16] O. Solin,et al. Automated synthesis and purification of [18F]bromofluoromethane at high specific radioactivity. , 2001, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[17] M. Berridge,et al. Synthesis of [18F]fluoromethyl iodide, a synthetic precursor for fluoromethylation of radiopharmaceuticals. , 2000, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[18] C. Maggi,et al. The tachykinin NK1 receptor. Part I: Ligands and mechanisms of cellular activation , 1997, Neuropeptides.
[19] H. Burns,et al. Radioiodinated L-703,606: a potent, selective antagonist to the human NK1 receptor. , 1994, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[20] R. Hargreaves,et al. An orally active, water-soluble neurokinin-1 receptor antagonist suitable for both intravenous and oral clinical administration. , 2001, Journal of medicinal chemistry.
[21] K. Yoshioka,et al. Neurotransmitter functions of mammalian tachykinins. , 1993, Physiological reviews.
[22] A. Fischman,et al. Synthesis of a 11C-labeled NK1 receptor ligand for PET studies. , 1995, Nuclear medicine and biology.
[23] P. McIntyre,et al. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist , 1998, British journal of pharmacology.